查看文章

Platinum is detectable in the plasma years after completion of cisplatin treatment. Although it has been hypothesized that circulating platinum contributes to the severity and persistence of cisplatin’s adverse effects, results have been inconsistent due to the lack of an effective pharmacokinetic model that takes into account time since therapy and the use of relatively small patient cohorts. Here, we report the largest pharmacokinetic study to date of 1,013 testicular cancer survivors (TCS) assessed 1-35 years after completion of cisplatin-based chemotherapy, and perform a genome-wide association study (GWAS) to assess genetic contributions to our pharmacokinetic phenotype computed from serum platinum levels. Eligible TCS given 300 or 400 (± 15 mg/m²) cisplatin underwent extensive audiometric testing and clinical examination, as well as completed questionnaires at the time of follow-up. We then built an …